Introduction
The natural history of seizure disorders should be taken into consideration in any study of outcome. The key to accurate assessment of prognosis is recruitment of patients at the same point in the course of the disorder. 1 Specialist epilepsy clinics have a higher representation of patients with refractory epilepsy and cross sectional studies in such populations invariably report low rates of seizure freedom. This factor accounts for the perceived poor prognosis of epilepsy in much of the early literature. Longitudinal, population-based studies in patients with new onset epilepsy provide a more reliable assessment of response to treatment. [2] [3] [4] [5] With the widespread use of high resolution brain magnetic resonance imaging it has been possible to identify underlying structural abnormalities in many Seizure (2005) Summary A total of 558 patients with a range of localization-related epilepsy syndromes starting treatment in a single centre were followed over a period of up to 20 years. Overall, 343 (62%) patients became seizure free for 12 months or more (responders), 92% of whom (57% of total population) remained in remission until the end of follow-up. Only 27 (5%) responders relapsed and subsequently developed refractory epilepsy. The remaining 215 (38%) patients never became seizure free for any 12-month period. There were no significant differences in outcome between cryptogenic (56% remission) and symptomatic (57% remission) epilepsies. Patients with underlying cortical atrophy (71% remission; p < 0.05) or cerebrovascular disease (70% remission; p < 0.01) did better, while those with traumatic brain injury (35% remission; p < 0.001) did worse than the remainder of the symptomatic group. Remission rates in patients with cortical dysplasias (60%), hippocampal atrophy (50%) and primary brain tumors (52%) appeared no different from those with other symptomatic epilepsies. Overall, 20-40% patients with each epilepsy syndrome reported no further seizures after starting AED treatment including 21% with hippocampal atrophy and 33% with cortical dysplasia. More than 50% of patients developing localization-related epilepsy during adolescence or in adulthood had a good outcome. Prognosis in those with underlying hippocampal atrophy or cortical dysplasia was not always bad. # 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
patients with localization-related epilepsy. 6 Our understanding of the prognosis of these symptomatic epilepsies, nonetheless, is largely based on studies carried out in specialist centers. Thus, it is widely believed that certain types of symptomatic epilepsies, such as those associated with hippocampal atrophy and malformations of cortical development, which are frequently encountered in these clinic populations, almost invariably respond poorly to pharmacotherapy. [7] [8] [9] However, in most parts of the world epilepsy is treated at its onset by nonspecialists. Many patients who respond to antiepileptic drugs (AED) treatment do not undergo brain imaging. It is only when they prove refractory to a range of AEDs that referral to a specialist centre is made and subtle structural abnormalities such as hippocampal atrophy are identified. 10 Populations of patients with newly diagnosed epilepsy are, therefore, required to assess accurately the response to AED treatment in symptomatic epilepsy syndromes. We carried out an outcomes study in patients with localization-related epilepsies diagnosed, treated and followed up at a single centre over a 20-year period. This study follows up our preliminary observations published in 2000 which was made in a smaller cohort of patients. 4 Nearly twice as many patients have now been followed up over a longer time period. Particular focus in this report has been placed on remission in patients with specific symptomatic epilepsy syndromes
Methods
Adolescent and adult patients with suspected seizure disorders were referred to the first seizure service at the Western Infirmary, Glasgow, Scotland, by general practitioners, accident and emergency physicians and other clinicians over a 20-year period. A structured protocol was used to collect clinical information and detailed histories were obtained from patients and witnesses regarding suspected seizures. Electroencephalography was performed as clinically indicated, and brain imaging was undertaken if localization related epilepsy was suspected. When a diagnosis of epilepsy was made, the first ever AED was prescribed and outcomes were monitored over a period of years. Patients were considered to have responded to treatment if they had no seizures for a minimum of 12 months on an unchanged treatment schedule. Remission was defined as having no further seizures after responding to treatment. Relapse occurred in responders in whom initial control was lost and whose epilepsy subsequently became pharmacoresistant. Patients who continued to report seizures were, by definition, considered to have uncontrolled epilepsy. The extent of control was assessed at the time of the patient's last hospital visit. End of follow up was 1st May 2003, when the last patient had been attending the clinic for 2 years.
Epidemiological data were collected by review of research case notes. Seizure types and syndromes were classified at the time of analysis according to the guidelines of the International League against Epilepsy. 11, 12 Data were collected on an electronic spreadsheet and analysed using Minitab for Windows (version 13.32). Patients who did not return for follow up or were persistently non-adherent to their prescribed medication were excluded from analysis. The x 2 test was used to analyse categorical data and the Bonferroni method was used to correct for multiple comparisons. The Mann-Whitney test was used for analysis of non-parametric continuous data.
Results
Between August 1981 and May 2001, 890 patients were diagnosed with epilepsy, all of whom were prescribed AED treatment. A total of 625 (70%) patients were classified as having localizationrelated epilepsy. Sixty-seven patients (11%) were excluded from analysis owing to insufficient fol- Response, seizure-free for at least 12 months; remission, control maintained until the end of follow-up; relapse, refractory epilepsy after initial response; uncontrolled, never free of seizures for any 12 months. a Idiopathic localization-related epilepsies were included with cryptogenic group for analysis of outcomes.
low-up information. Treatment outcomes were known for the remaining 558 (89%) patients. This cohort comprised 296 (53%) males and 262 (47%) females. The median age at onset (first seizure) was 33 years (range 1-93 years) and that at diagnosis was 35 years (range 11-93 years). Patients reported a median of 5 (range 1 to >100) seizures before stating treatment. None had previously received an AED for any indication. Overall, 303 (54%) patients were designated as having cryptogenic epilepsy. A further 244 (44%) had a structural lesion identified on brain magnetic resonance or computerised tomographic imaging and were classified as having symptomatic epilepsy. The remaining 11 (2%) patients had idiopathic localization-related epilepsy syndromes (6 benign epilepsy with centrotemporal spikes, 4 benign occipital epilepsy, 1 benign partial epilepsy of childhood.)
A total of 343 (62%) responded to treatment by becoming seizure free for a period of 12 months or more (Table 1) . Thirty-nine responders had a recurrence of seizures, in 27 of whom control was never regained. These individuals constituted 5% of the entire cohort (8% of all responders). Thus, seizures were well controlled until the end of follow up in 316 (57%) patients who were regarded as having achieved remission. The remaining 215 (38%) patients never achieved seizure freedom for any 12-month period. No significant differences were observed in outcomes between patients with symptomatic and cryptogenic epilepsies (Table 1) . Monotherapy was successful in 315 (92%) of the 343 responders, 77% of whom were taking their first AED. In patients failing initial monotherapy, a second regimen produced seizure control in 59 (17%) patients (42 alternative monotherapy, 17 duotherapy). Outcomes in the various localization-related epilepsy syndromes are listed in Table 2 . Patients with cerebral atrophy (71% remission, p < 0.05), and cerebrovascular disease (70% remission, p < 0.01) did better, while those with traumatic brain injury (35% remission, p < 0.001) did worse than the remainder of the symptomatic group. Those with underlying hippocampal atrophy (Table 3 ; 50% remission) or malformations of cortical development (Table 4 ; 60% remission) fared no worse than the other types of symptomatic epilepsy.
A number of patients suffered no further seizures after starting AED treatment. These ''immediate responders'' constituted 20-40% patients with each specific epilepsy syndrome (Table 2) . Interestingly, 21% patients with hippocampal atrophy and 33% with cortical dysplasia fell into this category. The probability of achieving an immediate response was highest for patients with epilepsy due to underlying cerebrovascular disease (40%) or cerebral atrophy (40%).
Patients who relapsed or remained uncontrolled had been seizure free for a median of 21 months (range 12-97 months). The risk of relapse was not significantly different between patients with cryptogenic (n = 15) or symptomatic (n = 12) epilepsies. Only one patient each with hippocampal atrophy and cortical dysplasia has relapsed to date. Twentysix of the 27 patients who relapsed were receiving monotherapy with 23 taking their first AED.
Discussion
In this population of patients with newly diagnosed localization-related epilepsy, 62% responded to treatment by becoming seizure free for 12 months or more. Overall, 57% of the complete cohort remained in remission until the end of follow up. More than half of these patients suffered no further seizures immediately after starting treatment. The probability of a good outcome was highest in patients with underlying cerebral atrophy and cerebrovascular disease, and lowest for those with post-traumatic epilepsy. Only 8% of initial responders went on to develop refractory epilepsy. The remaining 38% patients never achieved complete seizure control for any 12-month period and could be regarded as having refractory epilepsy de novo. 4 Mesial temporal lobe epilepsy is the commonest localization-related epilepsy syndrome, with hippocampal atrophy occurring in 50-70% of patients reporting uncontrolled seizures. 13 The incidence of refractory epilepsy in all patients with such hippocampal pathology, however, is unknown. Hospital-based case series have reported remission rates ranging from 11 to 42% with AED treatment depending on rates of referral from primary or secondary care. [7] [8] [9] 14, 15 Recent studies employing volumetry have identified hippocampal atrophy in patients with good seizure control 16, 17 and even in those without clinical or electroencephalographic evidence of mesial temporal lobe epilepsy. 18, 19 Thus, the relationship of hippocampal atrophy with refractory epilepsy, and indeed, with seizures themselves, is far from clear. Eight of the 14 patients who developed symptomatic epilepsy on the basis of underlying hippocampal atrophy responded to AED therapy with only one relapsing to date. Three patients never had another seizure after commencing AED therapy. Our data, therefore, suggest that the overall probability of remission in patients with this syndrome may be no worse than with other lesional epilepsies.
Malformations of cortical development have been increasingly recognised as the underlying cause of localization-related seizures with the widespread use of high quality brain imaging techniques. 20 In recent years, there has been a greater understanding of their genetic bases, clinical presentations, and epileptogenic mechanisms. 21 However, the prevalence of these abnormalities in the general population and in patients with epilepsy in not known. Subtle anatomical anomalies have been demonstrated in asymptomatic relatives of patients with cortical dysplasias and epilepsy. 22 Ten of the 15 patients with newly diagnosed cortical dysplasias responded to treatment with only one relapsing. Again, five of these patients never had another seizure after starting AED therapy. Thus, as with hippocampal atrophy, the relative contribution of these abnormalities to refractory epilepsy remains unclear.
The mechanism of action of the traditional AEDs and many of the newer ones are thought to be known. 23 Why they show varying efficacy in patients with the same underlying pathology is unclear. Several hypotheses on the substrates underlying the evolution of drug resistant epilepsy have been proposed. 24 These include ontogenic abnormalities in brain maturation, epilepsy induced alterations in networking, neuronal and glial properties in seizure prone areas such as the hippocampus, and the phenomenon of kindling and reorganisation of cortical tissue in response to seizure induced disturbances in oxygen supply. It is likely that response to drug treatment is governed by a number of genetic and environmental influences. 25 Genetic polymorphisms cause variations in the levels and activity of drug metabolising enzymes and transporter molecules and may affect the distribution and concentration of AEDs. 26, 27 Polymorphisms of drug targets may alter the affinity and activity of individual drugs. Similarly environmental factors, including lifestyle issues, such as abuse of proconvulsant recreational drugs, can affect the efficacy of AEDs. In such a complex multifactorial environment individual factors are likely to have limited predictive value. The epilepsy syndrome in an adult population is only one such variable.
